⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 10, 2019Journal of the American Society of NephrologyOpen Access

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

View Full Paper

Ask AI

Bookmark

Share

Abstract

With large enough sample sizes, GFR slope may be a viable surrogate for clinical end points in CKD RCTs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Inker et al. (2019) studied this question.

synapsesocial.com/papers/69dcc9097873f5f05b1340ba https://doi.org/10.1681/asn.2019010007

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical SimulationRCT · 2019 · 119 citations
2The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal DiseaseCohort Study · 1994 · 2,346 citations
3Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and MortalityCohort Study · 2014 · 980 citations
4Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease Results From the AASK TrialRCT · 2002 · 2,042 citations